Haematology 2018

HD13: Progression-free survival All patients (ITT)

1.0

0.9

0.8

0.7

5 year estimate [95%-CI] median observation time

0.6

2xABVD+IF:

93.3% [90.9% to 95.6%]

53 m

0.5

2xABV+IF:

82.0% [76.6% to 87.5%]

83 m

PFS

0.4

2xAVD+IF:

89.0% [86.1% to 91.9%]

55 m

0.3

2xAV+IF:

80.6% [74.7% to 86.5%] 82 m

0.2

0.1

ABVD

ABV

AVD

AV

0.0

0

12

24

36

48

60

72

Time [months]

Pts. at Risk

ABVD ABV AVD

623 209 620 186

593 189 592 166

556 178 540 153

490 170 477 144

362 156 344 128

228 139 230 118

130 109 126

AV

93

Behringer et al, Lancet 2014